For the Quarter Ending December 2025
North America
• In the USA, the Fusidic Acid Price Index rose by 6.87% quarter-over-quarter, reflecting inventory replenishment and pharmaceutical buying.
• The average Fusidic Acid price for the quarter was approximately USD 152953.33/MT, per CFR Houston landed-cost calculations.
• Fusidic Acid Spot Price eased as lower China-US freight and muted U.S. buying reduced landed-cost pressure.
• Fusidic Acid Price Forecast indicates near-term stability with marginal volatility from shipment timing and inventory.
• Fusidic Acid Production Cost Trend remained stable; offshore cGMP fermentation schedules and normal batch yields constrained variability.
• Fusidic Acid Demand Outlook stays narrow, driven by clinical trials, named-patient programmes and compounding pharmacy procurement.
• Fusidic Acid Price Index reflects balanced, slightly long supply, exporter discipline and downstream inventory-maintenance buying.
• Moderate Gulf Coast port congestion influenced timing of receipts, supporting steady Price Index and importer procurement schedules.
Why did the price of Fusidic Acid change in December 2025 in North America?
• Reduced ocean freight rates in December lowered landed costs, directly relieving logistics premiums on China-to-US shipments.
• Tepid U.S. buyer interest in an unapproved niche antibiotic reduced immediate procurement urgency and demand pull.
• Steady offshore production and disciplined exporter allocations increased available lots, slightly easing Price Index upward pressure.
APAC
• In China, the Fusidic Acid Price Index rose by 6.9% quarter-over-quarter, driven by export replenishment
• The average Fusidic Acid price for the quarter was approximately USD 152833.33/MT, supported by exports
• Fusidic Acid Spot Price eased modestly in December as overseas tenders delayed purchases into 2026
• Fusidic Acid Price Forecast suggests mild near-term softness unless unexpected tenders tighten export availability materially
• Fusidic Acid Production Cost Trend stayed steady due to ample glucose, peptone and flat steam
• Fusidic Acid Demand Outlook shows subdued December buying as hospitals paused procurement awaiting January tenders
• Fusidic Acid Price Index peaked earlier, then softened in December as exporters offered small concessions
• Domestic producers operated at nameplate rates, export warehouses normalized stocks, allowing reliable shipments for exporters
Why did the price of Fusidic Acid change in December 2025 in APAC?
• Export demand from India, Brazil, and Russia softened as tenders postponed, reducing immediate API purchases
• Finished-dosage buyers in China paused hospital procurement after reimbursement list update, trimming near-term offtake significantly
• Stable feedstock and steam costs kept production costs flat, allowing sellers to concede small export discounts
Europe
• In Germany, the Fusidic Acid Price Index rose by 6.86% quarter-over-quarter, driven by stronger procurement.
• The average Fusidic Acid price for the quarter was approximately USD 152911.67/MT in German imports.
• Fusidic Acid Spot Price eased December with shipments increasing availability and pressuring the Price Index.
• Fusidic Acid Price Forecast indicates recovery into Q1 as year-end replenishment supports cautious upward movement.
• Fusidic Acid Production Cost Trend remained stable as energy and feedstock prices constrained cost-driven upside.
• Fusidic Acid Demand Outlook remains stable as dermatology and hospital procurement replaces seasonal fluctuations with replenishment.
• Fusidic Acid Price Index reflected comfortable inventories and intra-EU flows, constraining suppliers' to raise quotes.
• Major European suppliers maintained normal output while Hamburg port efficiency reduced logistical premiums, supporting orderly market functioning.
Why did the price of Fusidic Acid change in December 2025 in Europe?
• Abundant EU and Indian arrivals boosted supply, exerting downward pressure on fusidic acid prices.
• Euro strength reduced import costs, trimming suppliers' quotations and nudging the Price Index lower.
• Routine port operations and adequate inventories reduced urgency, leaving buyers cautious, suppressing price recovery.
For the Quarter Ending September 2025
North America
• In USA, the Fusidic Acid Price Index rose by 7.95% quarter-over-quarter, reflecting firmer export offers.
• The average Fusidic Acid price for the quarter was approximately USD 143123.33/MT, reflecting import transactions.
• Fusidic Acid Spot Price firmed modestly as limited availability met steady exporter dispatch and demand.
• Fusidic Acid Price Forecast suggests mild upward bias as buyers replenish inventories before Q4 procurement.
• Fusidic Acid Production Cost Trend remained stable due to uninterrupted bio-fermentation runs and input supplies.
• Fusidic Acid Demand Outlook remains steady as pharmaceutical and veterinary offtake provide baseline consumption support.
• Fusidic Acid Price Index reflected exporter-driven offers while importer inventories stayed moderate, limiting abrupt volatility.
• Operational continuity in plants and smooth Gulf logistics supported supply reliability, constraining Price Index movements.
Why did the price of Fusidic Acid change in September 2025 in North America?
• Steady global exports and uninterrupted production reduced supply shocks, allowing importers to accept firmer offers.
• Stable bio-fermentation feedstock availability constrained production cost inflation, while freight remained range-bound, limiting upward pressure.
• Moderate importer inventories and pharmaceutical procurement ensured continuity, prompting suppliers to hold firm on offers.
APAC
• In China, the Fusidic Acid Price Index rose by 7.93% quarter-over-quarter, supported by stronger procurement.
• The average Fusidic Acid price for the quarter was approximately USD 142996.67/MT, market reported levels.
• Fusidic Acid Spot Price remained stable; downstream restocking absorbed volumes, keeping the Price Index firm.
• Fusidic Acid Price Forecast indicates modest gains as exporters maintain offers amid steady international inquiries.
• Fusidic Acid Production Cost Trend remained muted because feedstock availability supported uninterrupted fermentation operations efficiently.
• Fusidic Acid Demand Outlook shows pharmaceutical and veterinary procurement sustaining volumes without excessive buying pressure.
• Tight downstream inventories and sustained export inquiries supported the Fusidic Acid Price Index this quarter.
• Manufacturing operations ran uninterrupted, enabling timely shipments and limiting logistics premiums, supporting the Price Index.
Why did the price of Fusidic Acid change in September 2025 in APAC?
• Steady export demand and downstream restocking tightened supply, prompting the Fusidic Acid Price Index increase.
• Stable feedstock availability kept production costs muted, constraining significant upward pressure on API pricing overall.
• Uninterrupted inland logistics and port operations ensured timely shipments, preventing logistics-driven premiums amplifying price movements.
Europe
• In Germany, the Fusidic Acid Price Index rose by 7.93% quarter-over-quarter, due to tighter inventories.
• The average Fusidic Acid price for the quarter was approximately USD 143100.00/MT, remaining broadly stable.
• Tight distributor coverage supported the Fusidic Acid Spot Price as buyers prioritized availability over discounts.
• Short-term Fusidic Acid Price Forecast points to modest gains as replenishment and clinical buying resume.
• Fusidic Acid Production Cost Trend was muted; stable feedstock and freight limited immediate pass-through pressure.
• Fusidic Acid Demand Outlook remains steady with hospitals and dermatology manufacturers sustaining regular offtake levels.
• Inventory draws at downstream formulators tightened the Fusidic Acid Price Index, prompting shorter lead purchases.
• Exporters kept disciplined offers, supporting market tone while spot liquidity adjusted to confirmed order schedules.
Why did the price of Fusidic Acid change in September 2025 in Europe?
• Exporters raised offers amid stronger external demand, reducing discounting and tightening supply available for imports.
• Downstream inventory depletion at formulators and hospitals forced urgent procurement, elevating pressure and raising prices.
• Stable production and logistics avoided supply shocks, currency moves and export quotations increased landed costs.
For the Quarter Ending June 2025
North America
• Fusidic acid Spot Price in the U.S. experienced an upward trend during Q2 2025 with a modest 0.59% increase in April, 0.62% in May and 0.37% in June. It reached USD 133,190/MT by the end of the quarter and indicated a stable Price Index amid consistent global trade sentiment.
• Fusidic acid Price Forecast remains steady in the U.S. market as pharmaceutical manufacturers adhered to routine procurement cycles without speculative purchases. This helped in preventing price volatility despite minor global supply fluctuations.
• The Fusidic acid Production Cost Trend remained unaffected by upstream constraints as reliable production from key Asian origins ensured smooth CFR flows into Houston. No raw material shortages or cost shocks impacted overall price formation during Q2.
• Inventories across U.S. importers and distributors were proactively replenished in April amid tariff concerns. It led to moderate drawdowns through May and June as demand returned to equilibrium which supported steady downstream activity.
• No inland transport issues or logistical bottlenecks occurred throughout the quarter; port handling at Houston remained efficient, maintaining trade fluidity and keeping landed cost movements minimal.
• Domestic demand, a key component of the Fusidic acid Demand Outlook, was sustained by regular offtake from dermatological and antibiotic formulation units, with no seasonal spikes or promotional triggers distorting order volumes.
• The stable pricing environment was closely aligned with global benchmarks and reflected balanced parity with Asia-Pacific and European export offers, suggesting a controlled and synchronized international price environment.
• Buyers avoided forward bookings or bulk stocking, which further stabilized the import market and restricted speculative sentiment, keeping price correction scope narrow and aligning short-term consumption with on-hand inventory.
• Why did the price change in July 2025?
The Price Index for Fusidic Acid rose marginally in July 2025 due to persistent demand from pharmaceuticals and uninterrupted upstream supply, with no overstocking pressure or freight-related distortion.
Asia-Pacific (APAC)
• The Fusidic acid Spot Price in China followed a stable upward trajectory in Q2 2025, increasing 0.60% in April, 0.62% in May, and 0.38% in June, reaching USD 133,100/MT, driven by consistent overseas procurement and smooth production runs.
• The Fusidic acid Price Forecast for China remains neutral to moderately firm, with continued interest from international buyers in pharmaceutical and topical care formulations sustaining forward demand visibility.
• The Fusidic acid Production Cost Trend in Q2 remained steady as Chinese manufacturers faced no disruptions in intermediate supplies, and production hubs maintained optimal operational output with minimal regulatory interference.
• Inventory positions across Chinese export suppliers were carefully calibrated to match steady overseas offtake, ensuring that prices did not experience upward distortions due to stock shortages or holding pressure.
• Efficient port operations and uninterrupted inland logistics ensured timely dispatches, keeping supply chain resilience intact and contributing to a neutral freight impact on pricing for FOB contracts.
• Steady demand from Southeast Asia, the Middle East, and Europe upheld Chinese exports, with order sizes reflecting predictable purchase patterns, helping maintain pricing equilibrium.
• No signs of speculative stocking or advance procurement activity were reported during Q2, with exporters preferring routine cycle shipments and short-lead orders, contributing to gradual price appreciation.
• The Fusidic acid Demand Outlook remained anchored by regular buying from dermatology and hospital supply chains. However, the absence of volume surges kept market conditions rational and prevented price spikes.
• Why did the price change in July 2025?
The Price Index increased due to firm overseas demand and unchanged production cycles in early July 2025. The disciplined procurement from global partners supported a modest upward correction.
Europe
• The Fusidic acid Spot Price in Germany exhibited a stable upward slope through Q2 2025, rising by 0.60% in April, 0.63% in May, and 0.38% in June, settling at USD 133,195/MT, reflecting cautious yet consistent offtake across pharmaceutical sectors.
• The Fusidic acid Price Forecast suggests minimal deviation from current levels in Q3, with German buyers deferring bulk intake in June to pre-position themselves ahead of expected Q3 price recalibrations.
• On the Fusidic acid Production Cost Trend, upstream production hubs across Asia maintained regular output cycles, ensuring reliable inbound supply to Hamburg and preventing sudden cost-driven price pressures.
• Strategic inventory management in Q2 by German importers led to well-balanced stock levels, enabling buyers to resist aggressive restocking and instead rely on reserve volumes, thereby softening transactional urgency.
• No logistical slowdowns were reported at the Port of Hamburg or across inland freight routes, reinforcing trade stability and ensuring scheduled arrivals despite slight shipping rate adjustments absorbed at trade level.
• Pharmaceutical demand, as part of the Fusidic acid Demand Outlook, remained routine and focused on topical anti-infective and antibiotic therapies. No significant campaign-based purchases were reported through the quarter.
• Export origin stability played a key role in sustaining price alignment, as sellers maintained consistent FOB offers, limiting cost-push inflation and supporting controlled pricing in the German spot market.
• Currency parity between USD and EUR in May and June further helped stabilize prices, eliminating potential fluctuations from exchange volatility that could affect landed cost calculations.
• Why did the price change in July 2025?
The Price Index saw a minor increase in July 2025 due to continued demand stability and supply reliability. Buyers adopted a conservative procurement stance, but mild international firmness nudged the price upward.
For the Quarter Ending March 2025
North America
Fusidic Acid prices in the North American rose by an average of 1.37% during the first quarter of 2025. The market remained stable with steady buying activity from pharmaceutical and personal care industries. Demand was healthy but not aggressive. Procurement remained well-planned and buyers stuck to scheduled cycles. Distributors reported smooth logistics and there were no notable delays or congestion.
There was also no major fluctuation in supply, which helped maintain market confidence. Sellers did not push prices aggressively, but they remained firm due to consistent orders. In addition, there was some influence from recent tariff policies that encouraged early quarter procurement. Inventory levels remained comfortable, with most buyers avoiding overstocking. The transition from colder weather to milder temperatures brought minor logistical changes but did not cause disruption.
Overall, the price rise reflected a combination of steady demand, controlled procurement, and a calm trading environment. Buyers remained cautious, but market sentiment leaned positive. This led to a modest but noticeable increase in prices throughout the quarter. The trend was stable and supported by underlying sectoral consumption without any erratic shifts.
Asia Pacific
In Asia Pacific, Fusidic Acid prices rose by 1.72% during the first quarter of 2025. The Chinese Lunar New Year occurred during this quarter and resulted in short production pauses. This temporary slowdown affected availability for a brief period and prompted some buyers to plan their purchases earlier in the quarter. Demand from pharmaceuticals and skincare applications remained steady across the region. Buyers continued to place orders according to production needs, without large stockpiling.
Procurement remained disciplined, and logistics performance was stable in most areas. There were no major concerns reported in transportation or port activity. Suppliers were able to manage lead times effectively, ensuring routine dispatches. The rise in prices reflected consistent offtake from downstream sectors and careful planning by buyers.
While supply was slightly tighter at certain points, overall market activity stayed balanced. The moderate increase in price was supported by controlled inventories, healthy demand and minor adjustments due to the holiday period that affected the entire region. The market remained stable without abrupt swings in sentiment or availability.
Europe
Fusidic Acid prices registered a quarterly rise of 1.46% from end quarter of 2024 to first quarter of 2025. The market stayed firm and showed balanced behaviour. Demand remained consistent from the pharmaceutical sector, especially in dermatological and skincare applications. Buyers made purchases in smaller batches and aligned with production needs. There was no excess buying or pressure in the market.
Suppliers maintained adequate stock levels, ensuring continuous supply without significant lead time changes. Logistics also remained stable, with deliveries reaching on time across most parts of the region. There were no reported hurdles in supply routes or warehousing. The price increase was gradual and stemmed from routine demand and structured procurement. Although raw material costs stayed manageable, the steady rise in orders helped push prices upward.
There was no indication of panic or unusual activity in the market. Buyers continued to follow conservative inventory strategies, while sellers remained confident due to consistent downstream activity. Overall, the pricing trend remained positive but measured and reflected a calm market behaviour and a regular trade pattern without any sudden shifts.
